153 related articles for article (PubMed ID: 22622596)
1. A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines.
Sáfadi MA; Berezin EN; Oselka GW
J Pediatr (Rio J); 2012 May; 88(3):195-202. PubMed ID: 22622596
[TBL] [Abstract][Full Text] [Related]
2. Meningococcal conjugate vaccines: efficacy and new combinations.
Sáfadi MA; Barros AP
J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S35-44. PubMed ID: 16826310
[TBL] [Abstract][Full Text] [Related]
3. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
4. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
[TBL] [Abstract][Full Text] [Related]
5. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
LaForce FM; Djingarey M; Viviani S; Preziosi MP
Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of meningococcal serogroup C vaccine programmes.
Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
8. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.
Borrow R; Alarcón P; Carlos J; Caugant DA; Christensen H; Debbag R; De Wals P; Echániz-Aviles G; Findlow J; Head C; Holt D; Kamiya H; Saha SK; Sidorenko S; Taha MK; Trotter C; Vázquez Moreno JA; von Gottberg A; Sáfadi MA;
Expert Rev Vaccines; 2017 Apr; 16(4):313-328. PubMed ID: 27820969
[TBL] [Abstract][Full Text] [Related]
9. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
[TBL] [Abstract][Full Text] [Related]
10. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil.
Bricks LF
Rev Hosp Clin Fac Med Sao Paulo; 2003; 58(4):231-40. PubMed ID: 14534678
[TBL] [Abstract][Full Text] [Related]
12. WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.
Conterno LO; da Silva Filho CR; Ruggeberg JU; Heath PT
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD001834. PubMed ID: 21735387
[TBL] [Abstract][Full Text] [Related]
13. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.
Conterno LO; Silva Filho CR; Rüggeberg JU; Heath PT
Cochrane Database Syst Rev; 2006 Jul; (3):CD001834. PubMed ID: 16855979
[TBL] [Abstract][Full Text] [Related]
14. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
[TBL] [Abstract][Full Text] [Related]
15. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
16. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
19. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
Badahdah AM; Rashid H; Khatami A
Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
[TBL] [Abstract][Full Text] [Related]
20. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
